Alzheimer’s disease
One of the key drivers of a shift in CNS drugs hinges on the success or failure of Biogen’s aducanumab for Alzheimer’s disease.
According to a statement made by Cortexyme, the partial hold was placed on the development program for atuzaginstat after an FDA review of the trial data identified hepatic adverse events.
Switzerland-based AC Immune SA announced positive interim results from its ongoing Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease.
The decision by the FDA on the drug application was expected on March 7, but is now delayed until June 7, 2021.
Being studied for GAD, OCD, AD and spinocerebellar ataxia, Biohaven’s troriluzole has now struck out in 3 late-stage studies.
The COVID-19 pandemic that has upended life across the globe has also ignited a reawakening to the value of vaccines, and Hu believes the momentum will carry forward into the new year.
The primary endpoint was change from baseline to 76 weeks in the Integrated Alzheimer’s Disease Rating Scale (iADRS).
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
AB Science SA reported promising data from its Phase IIb/III trial of masitinib in patients with confirmed mild to moderate Alzheimer’s disease.
PRESS RELEASES